Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
BMR SOLUTIONS LTD	49 SOKOLOV STREET HERZLIA 46497

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
• C07K:PEPTIDES

• 2015 Application Filing Year
• A61K Class
• 16157 Applications Filed
• 11882 Patents Issued To-Date
• 73.55 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Turdiev, Azim	Caesarea, IL	5	23
# of filed Patents : 5 Total Citations : 23

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 8 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Oct 25, 2028

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

DATE PUBLISHED	PUBLICATION/PATENT NO.	PUBLICATION TYPE
April 25, 2017	US,9629893,B2   US9629893B2	GRANTED PATENT AS SECOND PUBLICATION
January 28, 2016	US,20160022758,A1   US20160022758A1	FIRST PUBLISHED PATENT APPLICATION

Full Text

US Patent No: 9629893

Agent derived from tortoise spleen stimulating mammalian hemopoiesis

---

Abstract

---

The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

 

• LAPS2021
• STCH2021
• FP2021
• FEPP2020
• I2017
• STCF2017
• P2016
• F2015
• AS2011
• PD2003

Date	Code	Event	Description
May 31, 2021	LAPS	LAPSE FOR FAILURE TO PAY MAINTENANCE FEES	free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY
May 31, 2021	STCH	INFORMATION ON STATUS: PATENT DISCONTINUATION	free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362
Apr 25, 2021	FP	LAPSED DUE TO FAILURE TO PAY MAINTENANCE FEE	Effective Date: Apr 25, 2021
Dec 14, 2020	FEPP	FEE PAYMENT PROCEDURE	free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY
Apr 25, 2017	I	Issuance
Apr 05, 2017	STCF	INFORMATION ON STATUS: PATENT GRANT	free format text: PATENTED CASE
Jan 28, 2016	P	Published
Jul 30, 2015	F	Filing
Aug 25, 2011	AS	ASSIGNMENT	free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TURDIEV, AZIM;REEL/FRAME:036897/0193 Owner name: BMR SOLUTIONS LTD., ISRAEL Effective Date: Aug 25, 2011
Sep 04, 2003	PD	Priority Date